$177.51 Million in Sales Expected for BioScrip Inc (BIOS) This Quarter

Wall Street analysts predict that BioScrip Inc (NASDAQ:BIOS) will announce $177.51 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for BioScrip’s earnings, with the lowest sales estimate coming in at $177.01 million and the highest estimate coming in at $178.00 million. BioScrip reported sales of $168.58 million during the same quarter last year, which would suggest a positive year over year growth rate of 5.3%. The company is expected to announce its next earnings results on Thursday, May 9th.

According to Zacks, analysts expect that BioScrip will report full-year sales of $754.46 million for the current financial year, with estimates ranging from $750.72 million to $761.65 million. For the next financial year, analysts anticipate that the firm will post sales of $800.52 million, with estimates ranging from $794.00 million to $807.03 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow BioScrip.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Friday, March 15th. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.11). The firm had revenue of $183.57 million during the quarter, compared to analyst estimates of $188.39 million. During the same period in the previous year, the company posted ($0.03) earnings per share. The business’s quarterly revenue was up .5% on a year-over-year basis.

BIOS has been the subject of a number of analyst reports. BidaskClub downgraded BioScrip from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 27th. Canaccord Genuity initiated coverage on BioScrip in a research report on Wednesday, December 12th. They set a “buy” rating and a $5.00 price objective for the company. Lake Street Capital upped their price target on BioScrip from $4.50 to $10.00 and gave the company a “buy” rating in a report on Friday, December 7th. Stephens downgraded BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 price target for the company. in a report on Monday, March 18th. Finally, Zacks Investment Research downgraded BioScrip from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $4.70.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Venor Capital Management LP boosted its holdings in BioScrip by 0.3% in the third quarter. Venor Capital Management LP now owns 14,475,087 shares of the company’s stock valued at $44,873,000 after purchasing an additional 50,000 shares in the last quarter. BlackRock Inc. lifted its stake in BioScrip by 28.8% in the fourth quarter. BlackRock Inc. now owns 9,807,734 shares of the company’s stock valued at $35,013,000 after buying an additional 2,191,490 shares during the last quarter. Vanguard Group Inc lifted its stake in BioScrip by 0.5% in the third quarter. Vanguard Group Inc now owns 5,987,679 shares of the company’s stock valued at $18,562,000 after buying an additional 27,904 shares during the last quarter. Vanguard Group Inc. lifted its stake in BioScrip by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock valued at $18,562,000 after buying an additional 27,904 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in BioScrip by 7.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,617,021 shares of the company’s stock valued at $9,342,000 after buying an additional 180,389 shares during the last quarter. 82.51% of the stock is owned by hedge funds and other institutional investors.

Shares of BioScrip stock traded up $0.19 on Friday, reaching $2.00. 4,158,300 shares of the company were exchanged, compared to its average volume of 1,294,713. BioScrip has a 1-year low of $1.79 and a 1-year high of $4.14. The company has a market cap of $231.95 million, a PE ratio of -4.08 and a beta of 0.76.

About BioScrip

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Recommended Story: How to calculate the intrinsic value of a stock

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.